MedTechIQ_3Helix InSight Engine-Beta
Preview
Open in TheBrain
Triple Helix Discovery Engine
Government: Roles
Funders
Funding: U.S. Federal
*Funding: HHS
*HHS: Contracts, Contractors & Awards
*BARDA: Contracts (IDIQ, GWACS, Etc.), Contractors & Awardees
*Contractors & Awardees: BARDA
Ridgeback Biotherapeutics
Organization & Developments: Ridgeback Biotherapeutics
Parents
Ridgeback Biotherapeutics
Children
*The EIDD-2801 antiviral is orally available and, in addition to COVID-19, is being developed for the treatment of seasonal and pandemic influenza under a contract awarded to Emory Institute for Drug Development by the National Institute of Allergy and Infectious Diseases (NIAID) and for Venezuelan and Eastern equine encephalitis virus (VEEV and EEEV) by the Defense Threat Reduction Agency (DTRA).
2018: Ridgeback Biotherapeutics LP announces licensing of mAb114, an experimental Ebola treatment, from the National Institute of Allergy and Infectious Diseases
2019: EIDD-2801 Contract 75N93019C00058 was awarded to Emory University on Sep 9, 2019 funded by NIAID for potential award of $15,995,056.
2019: Ridgeback Biotherapeutics LP announces receipt of Breakthrough Therapy designation from FDA for mAb114 (Ebola)
2020: Antivirals Rather Than Vaccines For COVID-19
2020: BARDA_Breakthrough Ebola Treatment Receives Contract from U.S. Government_BARDA
2020: FDA Clears the Way for Ridgeback Biotherapeutics to begin Human Testing of a Promising Potential Treatment for COVID-19
2020: FDA Clears the Way for Ridgeback Biotherapeutics to begin Human Testing of a Promising Potential Treatment for COVID-19
2020: Financial speculation surrounding coronavirus drug developed with taxpayer money
2020: Merck and Ridgeback Bio Collaborate to Advance Development of Novel Antiviral Candidate, EIDD-2801
2020: Ridgeback Biotherapeutics Announces MHRA Clearance to Begin Human Testing of EIDD-2801 in the UK for COVID-19 and the Start of Phase 1
2021: Merck says its new Covid pill reduces the risk of hospitalization, death by half for some patients_www.cnbc.com
2021: Merck’s Molnupiravir: When a Private-Public Partnership Bears Fruit
2021: Ridgeback Biotherapeutics and Merck Announce Preliminary Findings from a Phase 2a Trial of Investigational COVID-19 Therapeutic Molnupiravir
2021: U.S. government to buy $1 billion more worth of Merck's COVID-19 pill
Ridgeback is receiving funding for mAb114 production and development from the Biomedical Advanced Research and Development Authority (BARDA contract 75A0119c0059).
Jumps
*Key People: Ridgeback Biotherapeutics
Finance & Acquisitions: Ridgeback Biotherapeutics